Therapeutic Effects of Fenofibrate on Diabetic Peripheral Neuropathy by Improving Endothelial and Neural Survival in db/db Mice

Ye Rim Cho1, Ji Hee Lim1, Min Young Kim1, Tae Woo Kim1, Bo Young Hong2, Yong-Soo Kim1, Yoon Sik Chang1, Hye Won Kim2*, Cheol Whee Park1*

1 Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, 2 Rehabilitation Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Abstract
Neural vascular insufficiency plays an important role in diabetic peripheral neuropathy (DPN). Peroxisome proliferative-activated receptor (PPAR)α has an endothelial protective effect related to activation of PPARγ coactivator (PGC)-1α and vascular endothelial growth factor (VEGF), but its role in DPN is unknown. We investigated whether fenofibrate would improve DPN associated with endothelial survival through AMPK-PGC-1α-eNOS pathway. Fenofibrate was given to db/db mice in combination with anti-flt-1 hexamer and anti-flk-1 heptamer (VEGFR inhibition) for 12 weeks. The db/db mice displayed sensory-motor impairment, nerve fibrosis and inflammation, increased apoptotic cells, disorganized myelin with axonal shrinkage and degeneration, fewer unmyelinated fibers, and endoneural vascular rarefaction in the sciatic nerve compared to db/m mice. These findings were exacerbated with VEGF inhibition in db/db mice. Increased apoptotic cell death and endothelial dysfunction via inactivation of the PPARα-AMPK-PGC-1α pathway and their downstream PI3K-Akt-eNOS-NO pathway were noted in db/db mice, human umbilical vein endothelial cells (HUVECs) and human Schwann cells (HSCs) in high-glucose media. The effects were more prominent in response to VEGF inhibition. In contrast, fenofibrate treatment ameliorated neural and endothelial damage by activating the PPARα-AMPK-PGC-1α-eNOS-NO pathway in db/db mice, HUVECs and HSCs. Fenofibrate could be a promising therapy to prevent DPN by protecting endothelial cells through VEGF-independent activation of the PPARα-AMPK-PGC-1α-eNOS-NO pathway.

Introduction
Diabetic peripheral neuropathy (DPN) affects at least 50% of patients with diabetes, and is the leading cause of foot amputation [1,2]. Hyperglycemia is likely the primary factor [3], which is associated with changes in endoneural metabolism, including increases in the polyol pathway, advanced glycation and protein kinase C, impairment of essential fatty acid metabolism, defective neurotropic factors, and reduced nerve blood supply [4,5,6,7]. Human studies have found various histopathological anomalies in the sural nerve in patients with diabetes related to reduced blood flow [4]. Stevens et al. found that nerve blood flow fell by 80% on the fourth day following the induction of diabetes in rats [8]. Early physiological disorders such as nerve conduction showing and sensory loss can be used diagnosis, which is associated with reduced oxygen tension and peripheral vascular disease, and may predict onset of degenerative changes in neurons, Schwann cells and blood vessel [4,9,10]. The most widely and consistently reported structural change in the nerve trunks of streptozotocin-diabetic rats is reduced axonal caliber of myelinated fibers [11,12]. However, rodent models of DPN are frequently faulted as showing little reliable evidence of overt structural damage to myelome fiber such as the segmental demyelination, remyelination and Wallerian degeneration that characterizes human DPN [13].

Vascular endothelial growth factor (VEGF) is a critical component during the tissue growth and organ repair processes of angiogenesis and vasculogenesis and also is a survival factor for endothelial cells [14]. The two primary VEGF receptors on the vascular endothelium are VEGFR-1 (flk-1) and VEGFR-2 (flk-2). Besides its physiological actions, VEGF is vital for promoting the formation of collateral vessels after ischemic events and plays a key role in wound healing [14,15]. Moreover, it is clear that VEGF treatment via VEGFR-2 promotes neurotrophic effects in peripheral nervous system cells characterized by Schwann cell proliferation, stimulation of axonal outgrowth, and increased survival in both neurons and Schwann cells [16,17]. While therapeutic angiogenesis with VEGF and related molecules once held great promise for the treatment of DPN, it has not been successful to date. Therefore, alternative strategies that aim to stimulate revascularization of ischemic tissue are warranted [18,19]. Arany...
Effects of Fenofibrate on Diabetic Neuropathy

and colleagues recently reported that peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) stimulates angiogenesis in ischemic tissues [19]. They demonstrated that PGC-1α up-regulates angiogenic factors other than VEGF and stimulates revascularization of ischemic tissue. PGC-1α interacts with and coactivates many members of the nuclear receptor transcription factor superfamily. In the cardiovascular system, three major PGC-1α transcription factor partners have been identified: peroxisome proliferator-activated receptor (PPARα, estrogen related receptor (ERR) family and nuclear respiratory factor 1 (NRF-1) [20].

Lipid-lowering therapy with a fibrate may have benefits for DPN beyond its anti-atherogenic effects in type 2 diabetes [21]. Activation of PPARα attenuates or inhibits several vascular damage mediators, including lipotoxicity, inflammation, reactive oxygen species generation, endothelial dysfunction, and thrombosis. These protective effects may be influenced by the intracellular Phosphatidylinositol 3 kinase (PI3K)-Akt-endothelial nitric oxide synthase (eNOS) signaling pathway that underlies diabetic neuropathy [22,23,24]. Furthermore, fenofibrate stimulates AMP-activated kinase (AMPK)-eNOS expression in HUVECs, thereby increasing nitric oxide (NO) production, inhibiting NF-kB, and suppressing cellular adhesion molecules [24,25]. Pharmacological treatment with a fibrate increases PGC-1α due to an increase in mitochondrial biogenesis [26]. Moreover, direct regulation of PGC-1α though activation of PPARα has also been suggested [27].

Therefore, we investigated whether fenofibrate had a protective role against DPN in db/db mice through PGC-1α activation during blockade of VEGF-VEGFR signaling in diabetic mice. A selective anti-flt hexamer (anti-flt-1; GNQWFI) and an anti-flk-1 heptamer (anti-flk-1; ATWLPPR) inhibit VEGF-induced endothelial cell migration and morphogenesis via VEGFR-R1 inhibition [28] and VEGF-induced angiogenesis and endothelial cell proliferation via VEGFR-R2 inhibition, respectively, in both in vivo and in vitro model [19,20,21].

Materials and Methods

Experimental Methods

All experiments were performed in accordance with the institutional animal care guidelines, and all procedures complied with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 1996). Because loss of a single VEGF allele is lethal in mice embryos due to impaired angiogenesis and blood-island formation from P11-12 [28], VEGFR-1 and VEGFR-2 blockade was induced in the mice with a combination of GNQWFI (50 µg/kg) and ATWLPPR (50 µg/kg) peptides were subcutaneously injected into diabetic (db/db VEGFR12, n = 8) and non-diabetic (db/m VEGFR12, n = 8) mice daily for 12 weeks beginning at 8 weeks of age [29,30,31]. Fenofibrate (0.2%, w/w, Sigma, St. Louis, MO, USA) was given in the standard chow diet to diabetic mice (db/db VEGFR12, n = 8) and nondiabetic (db/m VEGFR12, n = 8) mice daily for 12 weeks beginning at 8 weeks of age [29,30,31]. Fenofibrate (0.2%, w/w, Sigma, St. Louis, MO, USA) was given in the standard chow diet to diabetic mice (db/db VEGFR12, n = 8). PECAM-1, 8-OH-dG, PPARα and the TUNEL assay. Micrographs of the pancreatic islets were captured by a digital camera (Olympus DP11; Olympus America, Melville, NY) by an examiner who was blinded to the tissue source. Each nerve section was sampled in a serpentine pattern such that the entire nerve section was analyzed with no overlapping fields. The number of endoneurial blood vessels was counted. This allowed for both quantification and morphological analysis of the endoneurial blood vessels. Ten consecutive nerve cross-sections were photographed and fixed in 4% paraformaldehyde. Trichrome-stained nerves were collected under general anesthesia. Some sciatic nerve samples were fixed in normal buffered 4% formalin for immunohistochemistry, and the others were stored in a solution for electron microscopy.

Ethics Statement

The study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Laboratory Animal Care Committee at the Catholic University of Korea (Permit Number; CUMC-2012-0110).

Assessment of Peripheral Nerve Function

Tactile responses and Sciatic motor nerve conduction studies (MNCS). Tactile responses were evaluated by quantifying the 50% paw withdrawal threshold in response to stimulation with flexible von Frey filaments (Touch-Test™ Sensory Evaluators, Stoelting Co., Wooddale, IL) as described by Chaplan et al [32]. MNCS was performed on the left sciatic nerve using an electromyographic device (Synergy, Medelec Ltd., Oldwoking, England), within 15 min of isoflurane anesthesia to avoid respiratory arrest. The sciatic nerve was stimulated supramaximally (2–3 mA, 0.1 ms) at the ipsilateral sciatic notch and motor response was obtained from the fifth inter-osseous muscle of the hindpaw. Compound muscle action potentials were measured from the stimulus to the onset of the negative M-wave deflection.

Blood Glucose, HbA1c and Lipid Profiles

After 12 weeks of treatment with fenofibrate, blood glucose was measured using an Accucheck meter (Roche Diagnostics, St. Louis, MO). Hemoglobin A1c (HbA1c) was determined on red cell lysates using high-performance liquid chromatography (BioRab, Hercules, CA). Total cholesterol (TC), high-density lipid cholesterol (HDL-C) and triacylglycerol (TG) concentrations were measured with an auto-analyzer (Hitachi 917, Tokyo, Japan) using commercial kits (Wako, Osaka, Japan).

Light- and Electron-microscopic Analysis

Nerve morphology. Sciatic nerve samples were collected and fixed in 4% paraformaldehyde. Trichrome-stained nerves were used to examine the effect of VEGFR inhibition on nerve fibrosis. Ten consecutive nerve cross-sections were photographed using a digital camera (Olympus DP11; Olympus America, Melville, NY) by an examiner who was blinded to the tissue source. Each nerve section was sampled in a serpentine pattern such that the entire nerve section was analyzed with no overlapping fields. The number of endoneurial blood vessels was counted. This allowed for both quantification and morphological analysis of the endoneurial blood vessels. Ten consecutive nerve cross-sections were photographed and fixed in 4% paraformaldehyde. Trichrome-stained nerves were collected under general anesthesia. Some sciatic nerve samples were fixed in normal buffered 4% formalin for immunohistochemistry, and the others were stored in a solution for electron microscopy.

Immunohistochemical techniques for transforming growth factor-β1 (TGF-β1), platelet-endothelial cell adhesion molecule-1 (PECAM-1), F4/80, 8-hydroxy-deoxyguanosine (8-OH-dG), PPARα and the terminal deoxynucleotidyl transferase dUTP nickend-labeling (TUNEL) assay. We performed immunohistochemistry for TGF-β1, PECAM-1, 8-OH-dG, PPARα and the TUNEL assay. Four-μm-thick sections were incubated overnight in a humidified chamber at 4°C with anti-TGF-β1, a profibrotic growth factor (1:100; R&D Systems, Minneapolis, MN); anti-PECAM-1, a mouse endothelial cell marker (1:100; Abcam, Cambridge, UK); anti-F4/80, an inflammatory cell marker (1:100; Santa Cruz Biotechnology, CA); the in situ TUNEL assay, an apoptotic marker (Chemicon-Millipore, Billerica, MA); 8-OH-dG, an oxidative

Effects of Fenofibrate on Diabetic Neuropathy
DNA damage marker (1:100; COSMO BIO, Tokyo, Japan); and PPARα (1:200; Abcam, Cambridge, UK).

**Immunofluorescence staining for DAPI, TUNEL and PECAM-1.** For immunofluorescence double staining, apoptosis was detected by ApoTag Fluorescein In Situ Apoptosis Detection Kit (S7110; Chemicon International, Temecula, CA). The ApoTag Fluorescein In Situ Apoptosis Detection Kit detects apoptotic cells in situ by the indirect TdT-mediated dUTP-biotin nick end labeling (TUNEL) method, using an anti-digoxigenin antibody that is conjugated to a fluorescein reporter molecule. Sections were incubated overnight with anti-PECAM-1 (1:50; Abcam, Cambridge, UK) and a Texas red-labeled secondary antibody and counterstained with the 4,6-diamidino2-phenylindole (DAPI).

**Electron microscopy.** For transmission electron microscopy (TEM), sciatic nerves specimens were fixed in 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer overnight at 4°C. After washing in 0.1 M phosphate buffer, the specimens were post-fixed with 1% osmium tetroxide in the same buffer for 1 hr. The specimens were then dehydrated using a series of graded ethanol, exchanged through acetone, and embedded in Epon 812. Ultrathin sections (70 nm) were obtained by ultramicrotome (Leica Ultracut UCT, Leica, Germany) and were double stained with uranyl acetate and lead citrate and examined in transmission electron microscope (JEM 1010, Tokyo, Japan) at 60 kV. We measured areas of unmyelinated fiber, axonal diameters and number of degenerative fiber using NIH Image J.

**Western Blot Analysis**

Western blot analysis was performed using the following antibodies: TGF-β1 (1:500; R&D Systems, Minneapolis, MN), platelet endothelial cell adhesion molecule (PECAM-1, 1:500; Abcam, Cambridge, UK), PPARα (1:100; Abcam, Cambridge, UK), PGC-1α (1:2000; Novus Biologicals, Littleton, CO), total-AMPK (1:1000; Cell Signaling Technology, Danvers, MA), phospho-Thr172 AMPK (1:1000; Cell Signaling Technology, Danvers, MA), P3K (1:1500; BD Biosciences, Franklin Lakes, NJ), total Akt, phospho-Ser473 Akt, total endothelial nitric oxide synthase (eNOS), and phospho-Ser1177 eNOS (1:1000; Cell Signaling Technology, Danvers, MA), and β-actin (Sigma-Aldrich, St Louis, MO). We also measured the concentration of NOx to quantify NO production in cell-culture media. We also performed similar experiment using Schwann cells.

**Data Analysis**

SPSS version 11.5 (SPSS, Inc., Chicago, IL) was used to conduct the statistical analysis. Group differences were evaluated using an analysis of variance (ANOVA) with Bonferroni’s correction. Non-normally distributed data were analyzed by the Mann-Whitney U-test. The results are expressed as mean ± SD. A P<0.05 was considered significant.

**Results**

**Body Weights, Glucose Levels, HbA1c Concentrations, and Lipid Profiles**

At the study’s conclusion, the average body weight of db/db mice was greater than that of db/m mice in both the VEGFR-inhibited and control groups (Table 1; P<0.001). No changes in body weight were noted in either db/m or db/db mice (with or without VEGFR inhibition) following the 12-week treatment with fenofibrate. Fasting blood sugar levels, HbA1c concentrations, and serum TG and TC levels were significantly higher in db/db mice than in db/m mice in both the VEGFR-inhibited and control groups (Table 1; P<0.001). Fenofibrate treatment resulted in a moderate yet significant decrease in both fasting blood glucose levels and HbA1c concentrations when compared with both non-treated diabetic db/db and db/db VEGFR12 mice (P<0.05). However, fenofibrate treatment did not affect serum TG levels of either db/db or db/m mice. In contrast, serum TC levels increased in both db/db and db/db VEGFR12 mice (P<0.05). Increased HDL-C levels were also observed in both db/db+Feno and db/db VEGFR12+Feno mice following fenofibrate treatment.

**Assessment of Peripheral Nerve Function**

**Tactile responses and sciatic motor nerve conduction.** Tactile response thresholds were increased in db/db mice compared to control db/m mice. Furthermore, the average tactile threshold response of db/db VEGFR12 mice exhibited a significant 2.6-fold increase compared to that of db/db mice. Importantly, fenofibrate treatment rescued tactile response thresholds in both db/db+Feno and db/db VEGFR12+Feno mice to levels comparable to that of db/m mice (Figure 1).

Sciatic motor latency was significantly delayed in db/db mice compared to db/m mice (Figure 1, 1.87 ± 0.18 vs. 1.51 ± 0.06 msec, P<0.01); furthermore, the sciatic motor latency delay in db/db VEGFR12 mice (2.15 ± 0.18 msec) was significantly greater than that in db/db mice (P<0.05). Consistent with their improved tactile responses, fenofibrate treatment restored sciatic motor latency in db/db+Feno and db/db VEGFR12+Feno mice to levels similar to that of non-diabetic db/m mice (1.59 ± 0.16 vs. 1.51 ± 0.06 msec).

These findings demonstrate that VEGFR inhibition significantly impairs sciatic motor nerve conduction in db/db mice, and that this impairment can be reversed by fenofibrate treatment.

Effects of Fenofibrate on Diabetic Neuropathy
Table 1. Body weight and biochemical characteristics of db/m and db/db mice under VEGFR inhibition treated with fenofibrate.

| Parameters       | db/m          | Feno | VEGFR12 | VEGFR12+Feno | db/db           | Feno | VEGFR12 | VEGFR12+Feno |
|------------------|---------------|------|---------|--------------|----------------|------|---------|--------------|
| Body weight (g)  | 31.6±1.6      | 28.9±2.3 | 31.4±2.2 | 29.3±0.9     | 49.5±3.3       | 46.3±3.5 | 44.3±4.6 | 51.8±3.1     |
| Glucose (mmol/l) | 9.3±0.6       | 8.5±1.1 | 10.2±0.9 | 8.4±0.7      | 29.1±3.6       | 21.7±4.3 | 27.5±4.1 | 20.1±7.4     |
| HbA1c (%)        | 5.2±0.2       | 5.1±0.3 | 4.8±0.4 | 5.2±0.2      | 11.3±1.5       | 9.75±2.0 | 11.1±1.9 | 9.42±1.7     |
| TC (mmol/l)      | 27.9±2.9      | 25.9±2.7 | 28.6±2.4 | 25.4±2.2     | 44.1±4.7       | 55.6±4.7 | 39.6±3.9 | 631±4.9      |
| HDL-C (mmol/l)   | 1.8±0.2       | 1.7±0.3 | 1.8±0.3 | 1.6±0.2      | 3.7±0.3        | 4.8±0.3  | 3.4±0.2  | 4.9±0.2      |
| TG (mmol/l)      | 1.05±0.29     | 1.28±0.23 | 1.22±0.15 | 1.34±0.28    | 1.72±0.17      | 1.59±0.21 | 1.96±0.14 | 1.74±0.22    |

Abbreviations: Feno; fenofibrate, TC; total cholesterol, HDL-C; high density lipoprotein-cholesterol, TG; triacylglycerol, VEGFR12; VEGFR-1 and –2 inhibition.

*P<0.01, **P<0.001 compared with db/m, db/m+VEGFR12, and db/m+VEGFR12+Feno groups.

Development of nerve fibrosis and expression of TGF-β1, PECAM-1, and HIF-1α.

In db/m mice, the sciatic nerve showed significantly more fibrosis in the trichrome-stained area than in either db/m or db/m VEGFR12 mice (Figure 2). Furthermore, immunohistochemical staining and Western blot analysis revealed a higher level of TGF-β1 expression in the sciatic nerve of db/m mice than in that of db/m and db/db VEGFR12 mice (Figure 2; P<0.05). TGF-β1 expression levels were also higher in db/db VEGFR12 mice than in db/db mice (P<0.01). Thus, a 12-week fenofibrate treatment course completely protected db/db and db/db VEGFR12 mice from increased sciatic nerve fibrosis and upregulation of TGF-β1 expression (P<0.01).

Immunohistochemical staining and Western blot analysis also revealed a marked decrease in PECAM-1 expression and an increase in HIF-1α expression in the sciatic nerve of control db/m mice compared with that of non-diabetic db/m mice (Figure 2). Furthermore, PECAM-1 was barely detected in the sciatic nerve of db/db+VEGFR12 mice (P<0.05), and HIF-1α expression was increased even more in db/db+VEGFR12 mice than in db/db mice. In contrast, PECAM-1 and HIF-1α expression levels in db/db+Feno and db/db+VEGFR12+Feno mice were restored to those of db/m mice. These effects were only observed upon fenofibrate treatment, and were not observed in untreated db/m mice.

F4/80-positive cells, 8-OH-dG expression, TUNEL- and PECAM-1-positive cells and PECAM-1 and TUNEL-double positive cells in the sciatic nerve.

Inflammatory cell infiltration, as defined by the presence of F4/80-positive cells, was more severe in db/m mice compared with non-diabetic db/m mice. Inflammatory cell infiltration was also more severe in db/db VEGFR12 mice than in db/db mice. Moreover, both db/db and db/db VEGFR12 mice showed higher levels of 8-OH-dG compared with db/m mice, reflecting increased neuronal oxidative stress (Figure 3). In both fenofibrate-treated groups, db/db+Feno and db/db+VEGFR12+Feno, production of 8-OH-dG decreased to levels comparable to that of db/m mice. However, VEGFR inhibition and fenofibrate treatment of db/m mice did not produce significant changes in either inflammatory cell infiltration or 8-OH-dG production. VEGFR inhibition increased the number of TUNEL-positive cells in db/m mice (Figure 3); however, compared with db/db VEGFR12 mice, fenofibrate treatment reduced the number of TUNEL-positive cells in db/db mice by one-third, resulting in a number comparable to that of db/m mice.

Diabetes induced a significant decrease in the density of endoneurial blood vessels in the sciatic nerve, an effect which...
was even more pronounced upon VEGFR inhibition (Figure 3). In contrast, fenofibrate treatment increased the number of endoneurial blood vessels. In order to further characterize the population of TUNEL-positive cells, we stained simultaneously for both TUNEL and PECAM-1. Consistent with the TUNEL-positive cell changes observed in the previous experiments, the number of PECAM-1 and TUNEL-double positive cells was increased in db/db mice, and was increased to an even greater extent in db/db VEGFR12 mice (Figure 3). Particularly noteworthy was the finding that fenofibrate treatment of both db/db and db/db VEGFR12 mice reduced the numbers of PECAM-1 and TUNEL-double positive cells to ones comparable to those of db/m mice. In contrast, no difference was observed in the number of PECAM-1 and TUNEL-double positive cells in db/m mice upon fenofibrate treatment (Figure 3 and data not shown). These findings suggest that vascular irregularities contribute to diabetes pathogenesis, and also that vascular irregularities combined with VEGFR inhibition drive further vascular dysfunction in the sciatic nerve by increasing endothelial cell apoptosis in the context of diabetes.

**Electron microscopy.** As assessed by ultrastructural studies, the sciatic nerve of db/db mice exhibited a decreased total area of unmyelinated fiber and decreased axonal diameter; furthermore, the sciatic nerve of db/db mice showed increased axonal degeneration (Figure 3). Diabetic mice with VEGFR inhibition also showed marked reductions in unmyelinated fiber area and axonal diameter, and a similar increase in axonal degeneration compared to diabetic mice (Figure 3). Of particular interest, sciatic nerves from fenofibrate-treated db/db mice (with or without VEGFR inhibition) harbored ultra-micro structures, resembling sciatic nerves from db/m control mice, in which the numbers of endoneurial blood vessels, areas of unmyelinated fiber, axonal diameters, and degrees of axonal degeneration were comparable to those of db/m control mice. Moreover, endoneurial blood vessels displayed endothelial cell disorganization, with basement membrane thickening in diabetic db/db VEGFR12 mice (Figure 3). The morphologies of endoneurial blood vessels in db/db+Feno, db/db VEGFR12+Feno, and db/m mice were all comparable.

**Sciatic nerve expression of PPARα, PGC-1α, total-AMP and phospho-AMPK(Thr172).** Immunohistochemical staining and Western blot analysis were next performed, and revealed that PPARα expression levels in db/db mice decreased significantly, by 40% and 60% respectively, compared with db/m mice (Figure 4). However, VEGFR inhibition in db/m mice did not change PPARα expression levels compared to db/m mice, whereas VEGF inhibition in db/db mice further decreased PPARα expression levels. Significantly, fenofibrate treatment increased PPARα expression levels in db/db mice compared to those of non-diabetic db/m mice. Furthermore, both PGC-1α expression levels and the ratios of phospho-Thr172/total AMPK were lower in db/db mice compared to those in db/m mice; VEGF inhibition further decreased these levels in db/db mice (Figure 4; P<0.05). However, the 12-week fenofibrate treatment course increased PGC-1α and phospho-AMPK(Thr172) expression levels in db/db mice to levels comparable to those of db/m mice.

**Effects of VEGFR Inhibition and Fenofibrate Treatment on HUVECs and HSCs.** We next examined the effects of high glucose in combination with VEGFR inhibition and fenofibrate treatment, and found that the amount of TUNEL-positive HUVECs only increased in high-glucose medium (Figure 5; P<0.01). Furthermore, VEGFR inhibition augmented the increase in TUNEL-positive HUVECs in high-glucose medium. The number of TUNEL-positive cells in high-glucose medium was markedly decreased by fenofibrate. However, fenofibrate treatment did not cause any significant differences in the numbers of TUNEL-positive HUVECs in low-glucose and 25 mmol/L mannitol medium, either with or without VEGFR inhibition.

The intracellular PGC-1α-P3K-Akt-eNOS signaling pathway is thought to play an important role in the maintenance of normal endothelial cell function [21,22]. To examine the effects of VEGFR inhibition and fenofibrate treatment on endothelial cell apoptosis and dysfunction in HUVECs, we investigated the expression levels of PPARα, PGC-1α, phosphorylated AMPK and P3K-Akt-eNOS signaling molecules in these cells. Significant decreases in the levels of phospho-AMPK(Thr172), a molecule involved in AMPK-PGC-1α signaling, phospho-Akt(Ser473), a molecule involved in P3K-Akt signaling, and phospho-eNOS (Ser1177) were noted in high-glucose medium (Figure 5). The expression levels of these proteins were decreased to an even greater extent by VEGFR inhibition. Consistent with these intracellular signaling changes, extracellular NOx concentrations decreased in high-glucose medium and decreased to an even greater extent upon VEGFR inhibition (Figure 5). Such changes were not observed at low glucose levels or under osmotic control, suggesting that extracellular glucose suppresses PGC-1α-phospho-AMPK and P3K-phospho-Akt-phospho-eNOS-NOS signaling pathways in HUVECs. Since fenofibrate stimulates PGC-1α expression [25,27], we also investigated the effects of VEGFR inhibition on PGC-1α expression levels and PGC-1α downstream signaling molecules in high-glucose medium. Notably, fenofibrate enhanced PGC-1α expression and AMPK phosphorylation. Moreover, fenofibrate activated P3K-Akt and eNOS-NOS signaling pathways to levels similar to those observed in low-glucose medium.

We also examined the effects of a high-glucose environment, either alone or in combination with VEGFR inhibition and fenofibrate treatment, on HSCs. Initially, we observed a significant increase in the number of TUNEL-positive HSCs when cells were cultured in high-glucose medium alone (Figure 6). Upon VEGFR inhibition in high-glucose medium, the number of TUNEL-positive HSCs was increased to an even greater extent. However, fenofibrate treatment markedly decreased the number of TUNEL-positive cells, even when cells were cultured in high-glucose medium. Furthermore, this decrease was also associated with a change in the Bcl-2/Bax ratio (Figure 6). However, no significant difference in the number of TUNEL-positive HUVECs was found when cells grown in low-glucose medium supplemented with 25 mmol/L mannitol (either with or without VEGFR inhibition).
Effects of Fenofibrate on Diabetic Neuropathy

A

B

C

D

E

F

G

H

I

J

K

L

M

N
Figure 3. Fenofibrate decreases inflammatory cell infiltration, oxidative stress and apoptosis of the sciatic nerve in db/db mice with VEGF inhibition. Representative immunohistochemical stain for F4/80-, 8-OH-dG- and TUNEL-positive cells and quantitative analyses of the results are shown (A to F). *P<0.05, **P<0.01 and ***P<0.001 versus db/m controls. Representative electron microscopic images of the sciatic nerve endoneural endothelial cells (15,000×) and nerve bundles (5,000×) (G and H). Disorganized, vacuolized and thickened endothelial cells were observed in db/db controls and db/db VEGFR12 mice. These characteristics decreased after 12-week fenofibrate treatment in the db/db+Feno and db/db VEGFR12+Feno mice. A marked decrease in the number of unmyelinated nerve bundles (red arrowheads) and prominent axonal degeneration (red arrows) were observed in the db/db controls and db/db VEGFR12 mice. These deficits were also improved by the 12-week fenofibrate treatment in the db/db+Feno and db/db VEGFR12+Feno mice. Quantitative analyses of number of endoneurial blood vessel, area of unmyelinated fiber, axonal diameter and number of degenerated axon are shown (I to L). *P<0.05 versus other groups, **P<0.01, and ***P<0.001 versus db/m controls. Representative immunofluorescent stains for PECAM-1 and TUNEL-double positive cells in db/db mice groups and quantitative analyses of the results are shown (M and N). An increase in the number of PECAM-1 and TUNEL-double positive cells (white arrows) was observed in the db/db controls and db/db VEGFR12 mice. **P<0.01 and ***P<0.001 versus db/m controls.

doi:10.1371/journal.pone.0083204.g003

Figure 4. Fenofibrate upregulates the expression of PPARα-PGC-1α-phospho-The172 AMPK in db/db mice with VEGF inhibition. Peroxisome proliferative-activated receptor (PPAR)α, PPARγ coactivator (PGC)-1α, phospho-The172/total AMPK and β-actin expression in the sciatic nerves of db/m and db/db mice after 12 weeks VEGF inhibition plus fenofibrate or VEGF inhibition alone. Representative immunohistochemical staining of PPARα and quantitative analyses of the results are shown (A and B). *P<0.05 versus db/m controls. Western blot analysis of PPARα, PGC-1α, phospho-The172/total AMPK and β-actin (C, respectively) and quantitative analyses of the results are shown. *P<0.05 and **P<0.01 versus db/m controls.

doi:10.1371/journal.pone.0083204.g004
with VEGFR12 inhibition, 5 Glu VEGFR12, or 5 Glu VEGFR12+Feno groups. Analysis of intracellular PPARα-PGC-1α-phospho-Thr172/total AMPK pathway and PI3K-Akt-eNOS signaling and apoptosis in cultured HUVECs. Representative Western blot of PPARα, PGC-1α and phospho-Thr172/total AMPK, and β-actin and quantitative analyses of the results are shown (C to F). Representative Western blot of PI3K, total and phospho-Ser1173 eNOS, and β-actin and quantitative analyses of the results are shown (G to J). The NOx concentrations from the supernatant of HUVECs are shown (K). *P<0.05 and **P<0.01 versus other groups. 5 Glu; 5 mmol/L D-glucose concentration, 5 Glu VEGFR12; 5 mmol/L D-glucose concentration with VEGFR12 inhibition, 5 Glu VEGFR12+Feno; 5 mmol/L D-glucose concentration with VEGFR12 inhibition+Feno; IV; 30 Glu; 30 mmol/L glucose, 30 Glu VEGFR12; 30 mmol/L D-glucose concentration with VEGFR12 inhibition; 30 Glu VEGFR12+Feno; 30 mmol/L D-glucose concentration with VEGFR12+Feno; Feno.

doi:10.1371/journal.pone.0083204.g005

Figure 5. Fenofibrate prevents high glucose-induced oxidative stress and apoptosis in HUVECs under VEGF inhibition. Marked increases in TUNEL-positive human umbilical vein endothelial cells (HUVECs) were observed in the 30 Glu group and 30 Glu VEGFR12 compared to the 5 Glu group with or without fenofibrate treatment. Quantitative analyses of the results are shown (A and B), *P<0.05, **P<0.01 and ***P<0.001 versus 5 Glu, 5 Glu VEGFR12, or 5 Glu VEGFR12+Feno groups. Analysis of intracellular PPARα-PGC-1α-phospho-Thr172/total AMPK pathway and PI3K-Akt-eNOS signaling and apoptosis in cultured HUVECs. Representative Western blot of PPARα, PGC-1α and phospho-Thr172/total AMPK, and β-actin and quantitative analyses of the results are shown (C to F). Representative Western blot of PI3K, total and phospho-Ser1173 eNOS, and β-actin and quantitative analyses of the results are shown (G to J). The NOx concentrations from the supernatant of HUVECs are shown (K). *P<0.05 and **P<0.01 versus other groups. 5 Glu; 5 mmol/L D-glucose concentration, 5 Glu VEGFR12; 5 mmol/L D-glucose concentration with VEGFR12 inhibition, 5 Glu VEGFR12+Feno; 5 mmol/L D-glucose concentration with VEGFR12 inhibition+Feno; IV; 30 Glu; 30 mmol/L glucose, 30 Glu VEGFR12; 30 mmol/L D-glucose concentration with VEGFR12 inhibition; 30 Glu VEGFR12+Feno; 30 mmol/L D-glucose concentration with VEGFR12+Feno; Feno.

doi:10.1371/journal.pone.0083204.g005

were treated with fenofibrate. The decrease in PPARα-AMPK-PGC-1α signaling observed in HSCs grown in high-glucose medium was markedly increased by fenofibrate treatment (Figure 6), suggesting that fenofibrate exerts a protective effect on the sciatic nerve and prevents the vascular damage inflicted by additional VEGFR12 treatment in db/db animals. In vitro studies also revealed that VEGFR12 treatment decreased the expression levels of key proteins in the PPARα-AMPK-PGC-1α signaling pathway, indicating that the effects of VEGFR12 on endothelial cell and neural damage, especially in Schwann cells, and the effects of fenofibrate on rescuing this damage, are mediated at least in part through the same pathway.

Discussion

The results presented here demonstrate that inhibition of VEGFRs with anti-VEGFR1 (GNQWFI) and anti-VEGFR2 (ATWLPKR) peptides aggravates DPN in type 2 diabetic mice. Inhibition of VEGFRs led to a decrease in the number of endoneurial blood vessels, a decrease in the area of unmyelinated fiber, a decrease in axonal diameter, and an increase in the amount of axonal degeneration in the sciatic nerve. These effects are all characteristics of human DPN, indicating that hypoxic nerve injury results from endoneurial and endothelial cell damage.

In contrast, fenofibrate treatment largely prevented the development of DPN, in a manner independent of VEGFRs, by activating the PPARα-AMPK-PGC-1α pathway. Moreover, in vitro studies provided direct evidence for the protective effects of fenofibrate against high glucose-induced endothelial cell damage. In these studies, fenofibrate activated the PPARα-AMPK-PGC-1α signaling pathway, leading to subsequent activation of downstream molecules such as PI3K and those involved in Akt-cNOS-NOx signaling. These findings are consistent with the previously proposed role of PPARα in PGC-1α activation, including the subsequent activation of the PI3K-Akt-cNOS signaling pathway [23,24]. Through this pathway, PPARα attenuates vascular damage in various ways, including reducing lipotoxicity, inflammation, the generation of reactive oxygen species, endothelial dysfunction, and angiogenesis in DPN. In addition, studies using HSCs cultured in vitro demonstrated that VEGFR inhibition decreased the expression levels of key proteins involved in PPARα-AMPK-PGC-1α signaling, indicating that the mechanisms by which VEGFR inhibition and hyperglycemia mediate nerve damage, and by which fenofibrate exerts a protective effect against this damage, require at least in part the same pathway.

The pathogenesis of DPN is not yet fully understood; however, ischemia and oxidative stress are thought to be involved [4,16,17]. The development of neuropathy in DPN may depend on the severity of hyperglycemia, which gradually damages the endothelium [33,34]. Serum lipid abnormalities, particularly elevated TG levels, appear to be strong predictors of microvascular complications in the neuron [35]. In the present study, no differences in TG levels were found in db/db mice, either with or without fenofibrate treatment. It is possible that fenofibrate-induced concomitant increases in HDL-C levels and decreases in blood glucose concentrations may have protective effects against DPN.

Microvascular insufficiency-related ischemia causes neuronal dysfunction, even in the absence of other metabolic abnormalities, because neuropathological changes in the peripheral nerves of non-diabetic patients with chronic hypoxia are quite similar to those found in DPN patients [4]. Vascular changes may be associated with secondary deficits in endothelial function resulting from impaired blood flow, such as impaired NO synthesis, release of NO upon endothelial injury by oxidative stress, and increased free radical activity [36]. Our study clearly demonstrates that VEGFR inhibition in diabetic mice increased endothelial and nerve damage, as indicated by a decrease in the number of PECAM-1-positive cells in the endoneurial blood vessels and increases in the numbers of TUNEL-positive, F4/80-positive, and PECAM-1 and TUNEL-double positive cells in the sciatic nerve upon VEGFR inhibition.

PPARα activation is known to have tissue-specific effects. In the nervous system, activated PPARα appears to be involved in neuronal differentiation, inflammation, and autoimmune modulation, and also protects nerves against ischemia [37,38]. Studies of retinal endothelial cells and HUVECs have demonstrated that fenofibrate- or pirinixic acid- (a PPARα agonist) mediated activation of AMPK increases NO production, inhibits NF-κB, and suppresses expression of genes encoding adhesion molecules [25,39,40]. These results suggest that endothelial cell protection and metabolic activities are tightly coordinated; however, it had not previously been determined whether diabetes affects PPARα or PGC-1α expression. Interestingly, PGC-1α is a metabolic sensor whose role is to stimulate angiogenesis in ischemic tissue such as in the nerve [19]. In the present study, diabetes decreased PGC-1α expression levels and suppressed AMPK-Akt-cNOS signaling. In the sciatic nerve, reduction of PPARα expression levels was especially pronounced upon VEGF inhibition; however, fenofibrate treatment restored PPARα expression to non-diabetic levels. These findings are consistent with a previous study demonstrating that fenofibrate suppressed microvascular inflammation and apoptosis by activating AMPK-Akt-cNOS signaling [41]. Various cytoprotective mechanisms of PGC-1α have been postulated, including activation of PI3K/Akt and secondary attenuation of p38 signaling, increased expression of survivin, and upregulation of Bcl-2 and/or inhibition of caspase-3 activity [41,42,43]. Most of these cytoprotective functions are associated with VEGF activation. In contrast, a recent study found that exercise-induced PGC-1α activation in the skeletal muscle of untrained elderly subjects actually increased angiogenesis, without activating VEGF [44]. In our study, we found that fenofibrate protected against endothelial and Schwann cell damage, and that the mechanism of fenofibrate-mediated protection of the sciatic
nerve involves activation of the AMPK-PGC-1α signaling pathway by PPARα, in a manner independent of VEGF.

In conclusion, this study demonstrates that hyperglycemia in diabetic mice aggravates DPN by increasing endothelial cell damage and inflammation of the sciatic nerve, and that these effects are aggravated by VEGF inhibition. Fenofibrate treatment prevented endothelial cell damage and inflammation of the sciatic nerve by activating PPARα-AMPK-PGC-1α signaling, in a VEGF-independent manner, leading to subsequent activation of PI3K-Akt-eNOS signaling in the sciatic nerve, HUVECs, and...

Figure 6. Fenofibrate prevents high glucose-induced oxidative stress and apoptosis in HSCs under VEGF inhibition. Marked increases in TUNEL-positive human Schwann cells (HSCs) were observed in the 30 Glu group and 30 Glu VEGFR12 compared to the 5 Glu group with or without fenofibrate treatment. Quantitative analyses of the results are shown (A and B, original magnification, ×1,000). **P<0.01 and #P<0.001 versus 5 Glu, 5 Glu VEGFR12, or 5 Glu VEGFR12+Feno groups. Western blot analysis of Bcl-2, Bax, and β-actin and quantitative analyses of the results are shown (C and D). *P<0.05 and **P<0.01 versus db/m controls. Analysis of intracellular PPARα-phospho-Thr172/total AMPK, PGC-1α, and β-actin and quantitative analyses of the results are shown (E to H). *P<0.05 and **P<0.01 versus other groups. 5 Glu; 5 mM D-glucose concentration, 5 Glu VEGFR12; 5 mM D-glucose concentration with VEGFR12 inhibition, 5 Glu VEGFR12+Feno; 5 mM D-glucose concentration with VEGFR12 inhibition+Feno; IV, 30 Glu; 30 mM glucose, 30 Glu VEGFR12; 30 mM D-glucose concentration with VEGFR12 inhibition; 30 Glu VEGFR12+Feno; 30 mM D-glucose concentration with VEGFR12+Feno. doi:10.1371/journal.pone.0083204.g006
Effects of Fenofibrate on Diabetic Neuropathy

Author Contributions
Conceived and designed the experiments: YRC JHL MYK TWK BYH YSC HWK CWP. Performed the experiments: YRC JHL MYK TWK BYH. Analyzed the data: YRC JHL MYK TWK YSC HWK CWP. Contributed reagents/materials/analysis tools: YRC JHL MYK TWK BYH YSC HWK CWP. Wrote the paper: CWP HWK YRC JHL.

References
1. Sima AA, Thomas PK, Ishii D, Vinik A (1997) Diabetic neuropathies. Diabetologia 40: B74–B77.
2. Greene DA, Steven MJ, Feldman EL (1999) Diabetic neuropathy: scope of syndrome. Am J Med 107: 28–88.
3. Diabetes Control and Complication Trial (DCCT) Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986.
4. Cameron NE, Eaton SE, Cotter MA, Tesfaye S (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetesologia 44: 1973–1988.
5. Van Dam PS (2002) Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Met Res Rev 18:176–184.
6. Green DA, Lattimer SA, Sima AA (1988) Perspectives in diabetes: are disturbances of sorbitol phosphatase and Naokie KATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 37: 608–693.
7. Aneel P, Terenghi G, Warner G, Kopleman P, Williams-Chesnut RE, et al. (1996) The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2: 703–707.
8. Stevens SJ, Carrington AL, Tomlinson DR (1994) Nerve ischemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models. Diabetologia 36: 1266–1274.
9. Young MJ, Yeves A, Walker MG, Boulton AJ (1992) Correlation between nerve conduction and tissue oxygenation in diabetes patients: further clues to the aetiology of diabetic neuropathy? Diabetesologia 35: 1146–1150.
10. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, et al. (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33: 2285–2293.
11. Britland ST, Sharma AK, Duguid IG, Thomas PK (1985) Ultrastructural observations on myelinated fibers in the tibial nerve of streptozotocin-diabetic rats: effect of insulin treatment. Life Support Syst Suppl 1: 525–529.
12. Jakobsen J (1976) Axonal dwindling in early experimental diabetes. I. A study of cross sectional nerves. Diabetologia 12:539–546.
13. Behse F, Buchhali F, Carlen F (1977) Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 40: 1072–1082.
14. Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Ann J Physiol Cell Physiol 280: C1358–C1366.
15. Nielsen NN, Poberjini P, Koch AE, Volland MV, Gannelli RL, et al. (1998) Vascular endothelial growth factor mediates angiogenesis during the vascular proliferative phase of wound healing. Am J Pathol 155: 1454–1452.
16. Schraberger P, Walter DH, Ringer K, Bahlmann FH, Pola R, et al. (2001) Reversal experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 107: 1083–1092.
17. Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor decreases diabetic reinnervation in the sciatic nerve of the rat. J Neurosci 19: 5731–5740.
18. Repper AH, Gorson KC, Gooch CL, Weinberg DH, Percek A, et al. (2009) Vascular endothelial growth factor gene transfer in diabetic neuropathy: a randomized and double-blinded trial. Ann Neurol 65: 306–309.
19. Arany Z, Foo SY, Ma Y, Ruas JL, BonniReedy A, et al. (2008) HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature 451: 1008–1012.
20. Finck BN, Kelly DP (2007) Peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1γ) regulates expression of PPARγ. J Clin Invest 115: 2540–2549.
21. Davis TM, Yeap BB, Davis WA, Bruce DG (2008) Lipid-lowering therapy and peripheral sensory neuropathy. Diabetologia 51: 562–566.
22. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, et al. (2006) Accelerated diabetic neuropathy in mice lacking the peroxisome proliferator-activated receptor α. Diabetes 55: 885–893.
23. Park CW, Kim HW, Lim JH, Yoo KD, Chung S, et al. (2009) Vascular endothelial growth factor inhibition by dnKox causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice. Diabetes 58: 2666–2676.